SCHEMBL1637442

SCHEMBL1637442

CCCN(CCC)CCCCNC(=O)c1ccc(CN(Cc2ccc(C)cn2)C(C)c2ncc[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.43
DRD4 P21917 3/20 0.43
DRD3 P35462 3/20 0.43
DRD2 P14416 1/20 0.43
OPRK1 P41145 7/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TMEM97 Q5BJF2 3/20 0.35
SIGMAR1 Q99720 3/20 0.35
DRD1 P21728 2/20 0.34
HTR2C P28335 2/20 0.34
DRD5 P21918 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1205352 0.87 CXCR4 (0.55) CXCR4DRD4DRD3DRD2OPRK1
SCHEMBL1205913 0.85 RORC (0.40) KMT2AALDH1A1MEN1
SCHEMBL1205966 0.84 DRD4 (0.51) CXCR4DRD4DRD3DRD2L3MBTL1
SCHEMBL1206006 0.84 CXCR4 (0.54) CXCR4DRD4DRD3DRD2OPRK1
SCHEMBL1637001 0.79 RORC (0.41) KMT2ASMN1; SMN2MEN1
SCHEMBL1206704 0.78 CXCR4 (0.49) CXCR4DRD4DRD3DRD2KMT2A
SCHEMBL1206818 0.77 CXCR4 (0.43) CXCR4DRD4DRD3DRD2TMEM97
SCHEMBL1638431 0.77 CXCR4 (0.52) CXCR4DRD4DRD3DRD2L3MBTL1
SCHEMBL1637445 0.76 CXCR4 (0.48) CXCR4DRD4DRD3DRD2OPRK1
SCHEMBL1638133 0.76 CXCR4 (0.51) CXCR4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US claimed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US claimed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP claimed
EP-1724263-B1 BASIC AMINE COMPOUND AND USE THEREOF KUREHA CORP (JP) 2014-03-05 EP disclosed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US disclosed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF NR0B2, NR5A2, NR1D2 CXCR4 86/4885DRD4 834/4885DRD3 283/4885
US-20070208007-A1 Amine-Based Compound and Use Thereof NR0B2, NR5A2, NR2E1 CXCR4 100/4885DRD4 1069/4885DRD3 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.